Predicting the outcome of radiotherapy for prostate carcinoma: A model- building strategy

Cancer

Volumn 82, Issue 7, 1998, Pages 1334-1342

  Ben Josef, Edgar ^a,b   Shamsa, Falah ^a   Forman, Jeffrey D ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Logistic model; Prognostic factors; Prostate carcinoma; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL RESEARCH; DISCRIMINANT ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; CARCINOMA; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0032055460     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980401)82:7<1334::AID-CNCR17>3.0.CO;2-7     Document Type: Article

References (52)

1. Killian CS, Yang N, Emrich LJ, Vargas FP, Kuriyama M, Wang MC, et al. The Investigators of the National Prostatic Cancer Project. Prognostic importance of prostate specific antigen for monitoring patients with stage B2 and D1 prostate cancer. Cancer Res 1985;45:886-91.
2. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:900-16.
3. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993;149:516-8.
4. Oesterling JE, Chan DW, Epstein JI, Kimball J, Bruzek DJ, Rock RC, et al. Prostatic specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988;139:766-72.
5. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993;20(4):713-25.
6. Cox RS, Kaplan IR, Bagshaw MA. Prostate-specific-antigen after external beam irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1994;28:23-31.
7. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam irradiation: follow-up. J Urol 1993;149:519-22.
8. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, Kinsella TJ. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
9. Russell KJ, Dunatov C, Hafferman MD, Griffeth JT, Polissar GL, Pelton J, et al. Prostate specific antigen in the management of patients treated with primary radiation therapy. J Urol 1991;146:1046-52.
10. Zagars GK. The prognostic significance of a single prostatic-specific antigen value beyond six months after radiation therapy of the prostate. Int J Radiat Oncol Biol Phys 1993;27:39-45.
11. Chauvet B, Felix-Faure C, Lupsascka N, Fijuth J, Brewer Y, Davin JL, et al. Prostate-specific antigen decline: a major prognostic factor for prostate cancer treated with radiation therapy. J Clin Oncol 1994;12(7):1402-7.
12. Kuban DA, El-Mahdi AM, Schellhammer PF. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995;32(2):307-16.
13. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, et al. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11(11):2158-66.
14. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC. Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 1995;32(2):293-306.
15. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151(3):640-5.
16. Ben-Josef E, Einav O, Forman DJ. Predicting the outcome of radiotherapy for localized prostate cancer using the pattern of PSA decline. J Clin Oncol 1993;12:230.
17. Kavadi VS, Zagars GK, Pollack A. Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 1994;30(2):279-87.
18. Zagars GK, Pollack A. The serum prostate-specific antigen level three months after radiotherapy for prostate cancer: an early indicator of response to treatment. Radiother Oncol 1994;30(2):121-7.
19. Landmann C, Hunig R. Prostatic specific antigen as an indicator of response to radiotherapy in prostate cancer. Int J Radiat Oncol Biol Phys 1989;17:1073-6.
20. Willett CG, Zietman AL, Shipley WU, Cohen JJ. The effect of pelvic radiation on serum levels of prostate specific antigen. J Urol 1994;151:1579-81.
21. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF Jr., Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostatic cancer. J Clin Oncol 1995;13(2):459-63.
22. Perez CA, Garcia D, Simpson JR, Zivnuska F, Lockett MA. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother Oncol 1989;16(1):1-21.
23. Pilepich MV, Krall JM, Sause WT, Johnson RJ, Russ HH, Hanks GE, et al. Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987;13(3):339-49.
24. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer 1993;72(5):1709-25.
25. Kim JA, Kuban DA, El-Mahdi AM, Schellhammer PF. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology 1995;194(2):545-9.
26. Roach M, Krall J, Keller JW, Perez CA, Sause WT, Doggett RL, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group protocols (1976-1985). Int J Radiat Oncol Biol Phys 1992;24(3):441-9.
27. Teshima T, Hanlon AM, Hanks GE. Pretreatment prostate-specific antigen values in patients with prostate cancer: 1989 patterns of care study process survey. Int J Radiat Oncol Biol Phys 1995;33(4):809-14.
28. Kuban DA, El-Mahdi AM, Schellhammer PF, Babb TJ. The effect of transurethral prostatic resection on the incidence of osseous prostatic metastasis. Cancer 1985;56:961-4.
29. Forman JD, Order SE, Zinreich ES, Lee DJ, Wharam MD, Mellits ED. The correlation of pretreatment transurethral resection of prostatic cancer with tumor dissemination and disease-free survival. A univariate and multivariate analysis. Cancer 1986;58:1770-8.
30. Landmann C, Hunig R, Rutishauser G. Adverse effect of transurethral resection on disease-free survival in locally advanced prostatic cancer treated with irradiation. Int J Radiat Oncol Biol Phys 1993;26(2):217-21.
31. McGowan DG. The adverse influence of prior transurethral resection on prognosis in carcinoma of prostate treated by radiation therapy. Int J Radiat Oncol Biol Phys 1980;6:1121-6.
32. Pilepich MV, Krall JM, Hanks GE, Sause WT, Baerwald H, Russ HH, et al. Correlation of pretreatment transurethral resection and prognosis in patients with stage C carcinoma of the prostate treated with definitive radiotherapy-RTOG experience. Int J Radiat Oncol Biol Phys 1987;13:195-9.
33. Beahrs OH, Henson DE, Hutter RVP, Myers MH. Manual for staging of cancer. American Joint Committee on Cancer. 4th edition. Philadelphia: J. B. Lippincott, 1992.
34. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111(1):58-64.
35. Homer D, Lemeshow S. Applied logistic regression. New York: John Wiley & Sons, 1989.
36. Katz D, Foxman B. How well do prediction equations predict? Using receiver operating characteristic curves and accuracy curves to compare validity and generalizability. Epidemiology 1993;4(4):319-26.
37. Gloeckler RLA, Hankey BF, Edwards BK, editors. Cancer statistics review: 1973-1987. Bethesda, (MD): National Cancer Institute; 1988 NIH Pub. No. 90-2789.
38. Byar DP, Code DK. Hormone therapy for prostate carcinoma: results of the Veteran Administration Cooperative Urological Research Group Studies. Monogr Natl Cancer Inst 1988(7):165-70.
39. Sarosdy MF. Do we have a rational plan for Stage D1 carcinoma of the prostate? World J Urol 1990;8:27-33.
40. Zincke H, Utz DC. Observations on surgical management of carcinoma of the prostate with limited nodal metastases. Urology 1984;24:137-45.
41. Zagars GK, Johnson DE, von Eschenbach AC, Hussey DM. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate: long term results of a prospective randomized study. Int J Radiat Oncol Biol Phys 1988;14:1085-91.
42. Ahelering TE, Lieskovsky G, Skinner DG. Salvage plus androgen deprivation for radioresistant prostatic adenocarcinoma. J Urol 1992;147:900-2.
43. Moul JW, Paulson DF. The role of radical surgery in the management of radiation recurrent and large volume prostate cancer. Cancer 1991;68:1265-71.
44. Pontes JE, Montie J, Klein E, Huben R. Salvage surgery for radiation failure in prostate cancer. Cancer 1993;71:976-80.
45. Zincke H. Radical prostatectomy and exenterative procedures for local failure after radiotherapy with curative intent: comparison of outcome. J Urol 1992;147:894-9.
46. Ben-Josef E, Shamsa F, Smith D, Forman JD. Early prediction of outcome of radiotherapy for localized prostate cancer using the pattern of PSA decline. Radiother Oncol 1994; 32(Suppl 1):S140.
47. Woodbury MA, Manton KG, Stallard E. Longitudinal models for chronic disease risk: an evaluation of logistic multiple regression and alternatives. Int J Epidemiol 1981;10(2):187-97.
48. Elnadt-Johnson RC. Time dependent logistic regression follow-up studies in clinical trials. I. Binary data. Institute of Statistics Mimeo Series No. 1310. Chapel Hill, NC: University of North Carolina, 1980.
49. Green MS, Symons MJ. A comparison of the logistic risk function and the proportional hazards model in prospective epidemiologic studies, J Chronic Dis 1983;36:715-23.
50. Ingram DD, Kleinman JC. Empirical comparisons of proportional hazards and logistic regression models. Stat Med 1989;8:525-38.
51. Lee A. Chapter 11: Identification of risk factors related to dichotomus data. In: Statistical methods for survival data analysis. 2nd edition. New York: John Wiley & Sons, 1992:305-6.
52. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335(8692):765-74.